Epidermolysis bullosa (EB)
What is Epidermolysis bullosa?
Epidermolysis bullosa (EB) is a rare genetic disorder that causes the skin to become extremely fragile and blister easily from minor trauma or friction. Often called “butterfly children” because their skin is as delicate as butterfly wings, people with EB face daily challenges from painful wounds and blistering. The condition affects approximately 1 in 20,000 births worldwide and involves defects in proteins that hold the layers of skin together. There are several types of EB, ranging from mild forms that primarily affect hands and feet to severe forms that can be life-threatening.
Key statistics
| Prevalence | ~1 in 20,000 births |
| Age of onset | Present from birth |
| Main types | 4 major types (EB simplex, junctional EB, dystrophic EB, Kindler syndrome) |
| Life expectancy | Variable: normal in mild forms, reduced in severe subtypes |
Symptoms
Skin blistering from minor trauma, chronic wounds, scarring, nail dystrophy, dental problems, feeding difficulties, growth delays, joint contractures.
The hallmark symptom of EB is the formation of fluid-filled blisters and erosions following minimal trauma or friction to the skin. In newborns, this may first appear after routine handling or diaper changes. The severity and distribution of blistering varies significantly between EB types. EB simplex typically affects the palms and soles, while more severe forms can involve the entire body surface, mucous membranes of the mouth, throat, and digestive tract.
Chronic wounds are common and heal slowly, often leaving scars that can cause significant deformity. In severe dystrophic EB, repeated scarring of the hands can lead to “mitten deformity,” where fingers become fused together. Nail abnormalities include thickening, ridging, or complete nail loss. Oral involvement can cause painful blisters in the mouth, dental decay, and feeding difficulties that may require nutritional support.
Internal complications may include blistering of the esophagus leading to swallowing difficulties, eye involvement causing vision problems, and in severe cases, blistering of internal organs. Growth delays are common due to nutritional challenges and the body’s energy expenditure on wound healing.
Causes and risk factors
Epidermolysis bullosa is caused by mutations in genes that produce proteins essential for skin integrity. The inheritance pattern varies by type: EB simplex is typically autosomal dominant (mutations in KRT5 or KRT14 genes), while junctional EB and recessive dystrophic EB follow autosomal recessive inheritance patterns (mutations in genes including LAMB3, LAMC2, COL7A1). Dominant dystrophic EB is inherited in an autosomal dominant pattern, also involving COL7A1 mutations.
These genetic defects affect structural proteins like keratins, laminin, or type VII collagen that normally anchor skin layers together. When these proteins are missing or dysfunctional, even minor mechanical stress causes the skin layers to separate and blister.
The primary risk factor is having parents who carry mutations in EB-associated genes. Carrier frequency varies by population and specific gene involved, with some estimates suggesting 1 in 200-300 people may be carriers for recessive forms.
Prevention
As a genetic condition, epidermolysis bullosa cannot be prevented through lifestyle modifications. However, genetic counseling and testing play crucial roles in family planning. Couples with a family history of EB or who are known carriers can undergo preconception genetic testing to understand their risk of having an affected child.
Prenatal diagnosis is available through chorionic villus sampling or amniocentesis for families with known EB mutations. Preimplantation genetic testing (PGT) may be an option for some couples using in vitro fertilization. Carrier testing can identify individuals who carry one copy of a recessive EB gene mutation, which is particularly important for recessive forms where both parents must be carriers for a child to be affected.
Complications
Without proper management, epidermolysis bullosa can lead to severe complications that significantly impact quality of life and survival. Chronic wounds may become infected, potentially leading to sepsis. Repeated scarring can cause joint contractures, limiting mobility and function. In severe forms, esophageal scarring can cause strictures that make swallowing difficult or impossible, requiring surgical intervention.
One of the most serious long-term complications is the development of aggressive squamous cell carcinoma (SCC), particularly in recessive dystrophic EB (RDEB). These cancers typically appear in areas of chronic wounds and scarring, often during adolescence or early adulthood. They tend to be more aggressive than typical skin cancers and represent a leading cause of mortality in severe EB.
Nutritional deficiencies are common due to oral and esophageal involvement, chronic inflammation, and increased nutritional needs for wound healing. This can lead to anemia, delayed wound healing, and growth retardation. Bone abnormalities may develop due to nutritional deficiencies and reduced mobility.
Diagnosis
Diagnosis of epidermolysis bullosa typically begins with clinical recognition of characteristic skin fragility and blistering patterns. A detailed family history helps identify potential inheritance patterns. The definitive diagnosis requires specialized testing to determine the specific EB type and subtype.
Skin biopsy with immunofluorescence mapping is often the first diagnostic test, examining how key structural proteins are distributed in the skin. Transmission electron microscopy can reveal the precise level where skin separation occurs, helping classify the EB type. Genetic testing through DNA sequencing identifies the specific gene mutations responsible, providing definitive diagnosis and enabling genetic counseling.
Additional tests may include complete blood count to check for anemia, nutritional assessments including iron, vitamin, and protein levels, and monitoring for complications. Regular dermatological surveillance is essential, particularly for squamous cell carcinoma in high-risk subtypes.
Treatment
Treatment for epidermolysis bullosa focuses on wound care, pain management, nutritional support, and prevention of complications. Advanced wound dressings that minimize trauma during changes are essential, including silicone-based products and specialized bandages. Pain management may require topical anesthetics and systemic medications.
A significant breakthrough came with the approval of beremagene geperpavec, the first gene therapy for dystrophic EB. This topical treatment delivers functional copies of the COL7A1 gene to promote healing of chronic wounds.
Nutritional support often involves high-calorie, high-protein diets, with supplements for vitamins and minerals. Severe cases may require feeding tubes or parenteral nutrition. Surgical interventions may be necessary for esophageal dilation, release of hand contractures, or treatment of complications.
Physical and occupational therapy help maintain function and prevent contractures. Psychological support is crucial given the chronic nature and visible impact of the condition. Regular monitoring for squamous cell carcinoma is essential, particularly in recessive dystrophic EB.
Prognosis
The prognosis for epidermolysis bullosa varies dramatically depending on the specific type and severity. Individuals with mild EB simplex may have near-normal life expectancy with manageable symptoms primarily affecting hands and feet. However, severe subtypes like junctional EB Herlitz type often result in death within the first two years of life due to complications.
Recessive dystrophic EB has an intermediate prognosis, with many individuals surviving to adulthood but facing significant morbidity from chronic wounds, scarring, and the risk of aggressive skin cancer. Advances in wound care, nutritional support, and recently approved therapies have improved outcomes significantly over the past decades.
Quality of life improvements are possible with comprehensive care, though the condition remains challenging. Early intervention, specialized multidisciplinary care, and family support contribute to better outcomes and adaptive functioning.
Quality of life
Living with epidermolysis bullosa requires significant daily adaptations to prevent skin trauma while maintaining as normal a life as possible. Clothing should be soft, loose-fitting, and seamless, with tags removed. Special shoes or custom orthotics may be necessary to protect feet. Environmental modifications include padding sharp corners, using soft furnishings, and maintaining moderate temperatures.
Diet modifications may be necessary if oral or esophageal involvement affects eating. Soft, cool foods are often better tolerated, and nutritional supplements may be required. Regular gentle exercise helps maintain joint mobility, though contact sports should be avoided.
Mental health support is crucial, as the visible nature of the condition and chronic pain can lead to depression, anxiety, and social isolation. Many individuals benefit from counseling, support groups, and connections with others who have EB. Educational accommodations may be necessary for children, including modified physical activities and understanding about medical absences.
Despite challenges, many people with EB lead fulfilling lives, pursuing education, careers, and relationships. Adaptive strategies and assistive technologies continue to expand possibilities for independence and participation.
Pregnancy and fertility
Fertility is generally not directly affected by epidermolysis bullosa, though severe forms may impact general health sufficiently to affect reproductive capacity. Pregnancy requires specialized care due to potential complications from skin fragility, nutritional demands, and the genetic implications for offspring.
Genetic counseling is essential before conception to discuss inheritance patterns and risk of transmitting EB to children. Prenatal diagnosis options should be reviewed for couples at risk. During pregnancy, careful monitoring of nutritional status, anemia, and skin integrity is important.
Delivery may require special considerations to minimize trauma, potentially including cesarean section in severe cases. Pain management during labor must account for existing EB medications and skin sensitivity. Breastfeeding may be challenging if there is significant oral or breast involvement, though many women with EB successfully nurse their babies.
Children
Epidermolysis bullosa presents unique challenges in pediatric care, as children are naturally active and may not understand the need to prevent skin trauma. Early diagnosis and family education are crucial for optimal management. Parents must learn specialized wound care techniques, recognize signs of infection, and balance protection with normal child development.
School accommodations are often necessary, including education for staff about EB, modified physical activities, and sometimes home schooling during severe flares. Social integration can be challenging due to the visible nature of the condition, making psychological support and peer education important.
Growth monitoring is essential, as nutritional challenges and chronic inflammation can affect development. Regular multidisciplinary care including dermatology, nutrition, orthopedics, and other specialists helps address the complex needs of children with EB.
When to see a doctor
Immediate medical attention is needed for signs of serious infection including fever, red streaking from wounds, increased pain, foul odor, or pus. New or changing skin lesions should be evaluated promptly, particularly in individuals with dystrophic EB due to cancer risk.
Routine care should include regular dermatology visits, nutritional assessments, and monitoring for complications. Difficulty swallowing, significant weight loss, or new joint limitations warrant prompt evaluation. Any concerns about wound healing, pain management, or new symptoms should be discussed with the healthcare team.
Establishing care with EB specialists or centers experienced in rare diseases is highly recommended for optimal management and access to newest treatments.
Regional context
Specific prevalence data for epidermolysis bullosa in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean is limited, though the condition occurs worldwide with similar frequency. Some populations may have higher rates of specific EB subtypes due to founder effects or consanguineous marriages.
Regional challenges may include access to specialized care, advanced wound dressings, and genetic testing. International collaborations and telemedicine consultations can help bridge gaps in expertise. The Global Medical Journal welcomes contributions from healthcare providers in these regions to better understand local prevalence, challenges, and successful management strategies.
Research and clinical trials
Research in epidermolysis bullosa is rapidly advancing with multiple therapeutic approaches under investigation. Gene therapy, protein replacement therapy, stem cell treatments, and novel wound care products are in various stages of development. Recent breakthroughs include the approval of beremagene geperpavec and ongoing trials of other gene therapies.
Cell-based therapies using mesenchymal stem cells, bone marrow transplantation, and tissue engineering approaches show promise. Drug repositioning studies are exploring existing medications that might benefit EB patients, including antifibrotic agents and anti-inflammatory therapies.
Patients and families can search for relevant clinical trials at ClinicalTrials.gov using keywords “epidermolysis bullosa.” Participation in research studies may provide access to experimental treatments while contributing to medical advancement for future generations with EB.
Frequently asked questions
Is epidermolysis bullosa contagious?
No, epidermolysis bullosa is a genetic condition that cannot be transmitted through contact. It is safe to touch, hug, or be near someone with EB, though gentle handling is important to prevent causing blisters.
Will my child with EB ever have normal skin?
While current treatments cannot cure EB or completely normalize skin, significant improvements in quality of life are possible with proper care. Gene therapy and other emerging treatments offer hope for better outcomes in the future.
Can people with EB have children?
Yes, many people with EB can have children. Genetic counseling is important to understand inheritance risks and discuss reproductive options including prenatal testing and assisted reproductive technologies.
How painful is epidermolysis bullosa?
Pain levels vary significantly between individuals and EB types. While some experience chronic pain requiring ongoing management, others have minimal discomfort. Effective pain management strategies are available and should be individualized.
Are there any activities people with EB should completely avoid?
While contact sports and activities with high trauma risk should generally be avoided, many people with EB participate in swimming, adapted sports, and other activities with appropriate precautions. Activity recommendations depend on EB severity and individual circumstances.
Support and resources
- DEBRA International – Global network of patient organizations (debra-international.org)
- National Organization for Rare Disorders (NORD) – Comprehensive EB information (rarediseases.org)
- Orphanet – European reference portal for rare diseases (orpha.net)
- EURORDIS – European organization for rare diseases (eurordis.org)
- EB Research Partnership – Funding research for EB treatments (ebresearch.org)
- Jackson Gabriel Silver Foundation – Supporting families affected by EB (jgsilver.org)
Related conditions
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Epidermolysis bullosa.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/epidermolysis-bullosa/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?